Clinical Trials Sponsored by Helena Laroche

Total 3494 results

Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Lymphoma, Follicular

France, United States
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Huntington's Disease

Germany, Canada, United Kingdom
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
Hoffmann-La Roche

Completed

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors (GARDENIA)

Ulcerative Colitis

Spain, United Kingdom, Belgium, Korea, Republic of, Austria, Czechia, France, Hungary, Italy, Netherlands, Singapore, Portugal, Canada, Germany, South Africa, Switzerland, Romania, Norway, Sweden, Israel
Hoffmann-La Roche

Terminated

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Small Cell Lung Cancer

Korea, Republic of, United States, Denmark, Spain
Hoffmann-La Roche

Terminated

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Bladder Cancer

United States
Hoffmann-La Roche

Completed

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

Huntington's Disease

United Kingdom, United States, Germany, Canada
Hoffmann-La Roche

Terminated

A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

Autism Spectrum Disorder

United States, Canada, France, Italy, Spain, United Kingdom
Hoffmann-La Roche

Completed

Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System (PRO Solo)

Diabetes Mellitus, Type 1

Austria, Germany, Poland, United Kingdom
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors (LAUREL)

Colitis, Ulcerative

Israel, United States, Hungary, India, Canada, Poland, Ukraine, Germany, Mexico, Brazil, Czechia, Slovakia, Denmark, South Africa, Italy
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)

Carcinoma, Non-Squamous Non-Small Cell Lung

United States, Israel, Belgium, Canada, Spain, Germany, Italy, France
Hoffmann-La Roche

Completed

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (HIBISCUS II)

Ulcerative Colitis

Australia, Czechia, France, Russian Federation, Malaysia, Bulgaria, United States, Croatia, Poland, Ukraine, Hungary, Colombia, New Zealand, Argentina, Turkey, Latvia, Brazil, Lithuania, Greece
Hoffmann-La Roche

Withdrawn

A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer (CATHAYA)

Carcinoma, Non-Small Cell Lung
Hoffmann-La Roche

Completed

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

United States, Australia, Italy
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Multiple Myeloma

United States
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
Hoffmann-La Roche

Terminated

A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder

United States
Hoffmann-La Roche

Terminated

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) (TRAXHER2)

Breast Cancer | Gastric Cancer

Italy, Argentina, Canada, France, Greece, Portugal, Slovakia, Brazil, Russian Federation, Spain, Germany, Serbia
Hoffmann-La Roche

Completed

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

Lung Diseases, Interstitial

Belgium, United Kingdom, Australia, Czechia, Germany, Poland, Denmark, Italy, Israel, Portugal, Spain, Ireland, Canada, Greece
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Taiwan, Thailand, New Zealand, Singapore
Hoffmann-La Roche

Completed

HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy

Breast Cancer

Germany
Hoffmann-La Roche

Completed

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Diabetes Mellitus Type 2

Australia, Hong Kong, Romania, United States, Japan, Russian Federation, Spain, Canada, Germany, Latvia, Mexico, Brazil
Hoffmann-La Roche

Completed

Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension

Idiopathic Pulmonary Fibrosis

Hungary, Belgium, Germany, Netherlands, Italy, Israel, Spain, Canada, South Africa, Turkey, Czechia, Egypt, Greece
Hoffmann-La Roche

Completed

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (AVENUE)

Choroidal Neovascularization

United States
Hoffmann-La Roche

Completed

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SCHEARLY)

Breast Cancer

Italy
Hoffmann-La Roche

Terminated

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Solid Tumors

Spain, Belgium, Denmark, Canada
Hoffmann-La Roche

Completed

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Lymphoma

Italy
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.

Healthy Participants

Hong Kong
Hoffmann-La Roche

Completed

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

Healthy Volunteers

United States
Hoffmann-La Roche

Completed

A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants

Healthy Volunteers

United States
Hoffmann-La Roche

Completed

A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants

Healthy Volunteers

France
Hoffmann-La Roche

Completed

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Influenza

United States, Poland, Russian Federation, Costa Rica, Mexico, Spain, Israel
Hoffmann-La Roche

Completed

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Juvenile Idiopathic Arthritis

Canada, Mexico, United States, Argentina, Germany, Israel, Italy, Russian Federation, Spain, United Kingdom
Hoffmann-La Roche

Completed

Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

Chronic Lymphocytic Leukemia

Argentina
Hoffmann-La Roche

Completed

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-angle

United States
Hoffmann-La Roche

Terminated

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (McCAVE)

Colorectal Cancer

United States, Spain, United Kingdom, Australia, Belgium, France, Austria
Hoffmann-La Roche

Completed

A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

Metastatic Colorectal Cancer

Belgium
Hoffmann-La Roche

Completed

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps (POLYP 2)

Nasal Polyps | Chronic Rhinosinusitis

Spain, United States, Belgium, France, Poland, Hungary, Finland, Mexico, Russian Federation, Ukraine
Hoffmann-La Roche

Completed

A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer (HerSCin)

Breast Neoplasms

Germany
Hoffmann-La Roche

Completed

Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

Rheumatoid Arthritis

France
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (ATALK)

Carcinoma, Non-Small-Cell Lung

France
Hoffmann-La Roche

Completed

Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

Multiple Myeloma

United States, Australia, United Kingdom
Hoffmann-La Roche

Completed

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

Giant Cell Arteritis

United States, United Kingdom, Sweden, Belgium, Netherlands, Germany, Spain, Norway, Poland, France, Italy, Canada, Denmark, Portugal
Hoffmann-La Roche

Completed

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Lymphoma

United States, France, Germany, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Coronary Heart Disease

Germany, United States
Hoffmann-La Roche

Completed

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

Solid Tumors

United States, Denmark, Spain, Switzerland, Netherlands, Canada
Hoffmann-La Roche

Completed

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Malignant Melanoma

South Africa
Hoffmann-La Roche

Terminated

A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Metastatic Breast Cancer

Saudi Arabia

3

Subscribe